Clinical Trial

ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to assess the safety and efficacy of ANO31905 in combination with chemotherapy as the first-line treatment for subjects with CLDN18.2-positive locally advanced unresectable or metastatic pancreatic cancer.
Protocol Amendment History 1 change
critical Recruitment opened 2026-07-28
Trial Details
NCT Number NCT07444541
Lead Sponsor Anova Innovation Limited
Conditions Pancreatic Cancer
Enrollment 84 participants
Start Date 2026-08
Primary Completion 2027-08 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-27